Analysts Issue Forecasts for RCUS FY2030 Earnings

Arcus Biosciences, Inc. (NYSE:RCUS) – Research analysts at HC Wainwright issued their FY2030 earnings per share (EPS) estimates for Arcus Biosciences in a note issued to investors on Thursday, February 26th. HC Wainwright analyst E. Bodnar expects that the company will earn $0.30 per share for the year. HC Wainwright currently has a “Buy” rating and a $32.00 price target on the stock. The consensus estimate for Arcus Biosciences’ current full-year earnings is ($3.15) per share.

A number of other brokerages have also recently issued reports on RCUS. UBS Group reissued a “buy” rating on shares of Arcus Biosciences in a report on Monday, December 15th. Wells Fargo & Company set a $23.00 price objective on Arcus Biosciences and gave the stock an “equal weight” rating in a research note on Thursday, February 12th. Citigroup restated a “buy” rating on shares of Arcus Biosciences in a research note on Friday, December 12th. Truist Financial set a $30.00 target price on shares of Arcus Biosciences in a report on Friday, December 12th. Finally, Bank of America increased their target price on shares of Arcus Biosciences from $17.00 to $26.00 and gave the stock a “neutral” rating in a research report on Friday, November 28th. Seven research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $29.33.

Arcus Biosciences Stock Performance

NYSE:RCUS opened at $20.36 on Friday. The firm has a market capitalization of $2.55 billion, a PE ratio of -6.17 and a beta of 0.84. The company has a quick ratio of 3.65, a current ratio of 3.65 and a debt-to-equity ratio of 0.22. Arcus Biosciences has a 12-month low of $6.50 and a 12-month high of $26.40. The firm has a 50-day moving average price of $21.57 and a 200 day moving average price of $18.50.

Arcus Biosciences (NYSE:RCUS) last released its quarterly earnings data on Wednesday, February 25th. The company reported ($0.89) EPS for the quarter, topping analysts’ consensus estimates of ($1.11) by $0.22. The company had revenue of $33.00 million during the quarter, compared to the consensus estimate of $24.94 million. Arcus Biosciences had a negative net margin of 142.91% and a negative return on equity of 69.86%. The firm’s revenue for the quarter was down 8.3% compared to the same quarter last year. During the same period last year, the firm earned ($1.03) EPS.

Insider Buying and Selling at Arcus Biosciences

In other news, General Counsel Carolyn C. Tang sold 7,658 shares of the firm’s stock in a transaction on Tuesday, December 16th. The stock was sold at an average price of $21.88, for a total value of $167,557.04. Following the transaction, the general counsel directly owned 131,544 shares in the company, valued at $2,878,182.72. This trade represents a 5.50% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, COO Jennifer Jarrett sold 11,225 shares of Arcus Biosciences stock in a transaction on Tuesday, December 16th. The stock was sold at an average price of $21.88, for a total value of $245,603.00. Following the sale, the chief operating officer directly owned 203,007 shares of the company’s stock, valued at approximately $4,441,793.16. This trade represents a 5.24% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders have sold 263,987 shares of company stock valued at $6,025,620. 9.60% of the stock is currently owned by corporate insiders.

Institutional Trading of Arcus Biosciences

A number of large investors have recently made changes to their positions in the company. AQR Capital Management LLC increased its holdings in shares of Arcus Biosciences by 253.9% in the first quarter. AQR Capital Management LLC now owns 90,954 shares of the company’s stock worth $714,000 after acquiring an additional 65,254 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in Arcus Biosciences by 10.5% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 37,572 shares of the company’s stock worth $297,000 after purchasing an additional 3,565 shares in the last quarter. Millennium Management LLC raised its holdings in Arcus Biosciences by 29.2% during the 1st quarter. Millennium Management LLC now owns 1,194,622 shares of the company’s stock worth $9,378,000 after buying an additional 270,253 shares during the period. Goldman Sachs Group Inc. lifted its stake in Arcus Biosciences by 106.2% in the first quarter. Goldman Sachs Group Inc. now owns 914,208 shares of the company’s stock valued at $7,177,000 after buying an additional 470,755 shares in the last quarter. Finally, Strs Ohio acquired a new position in shares of Arcus Biosciences in the first quarter valued at approximately $67,000. Institutional investors own 92.89% of the company’s stock.

Arcus Biosciences News Summary

Here are the key news stories impacting Arcus Biosciences this week:

• Positive Sentiment: Q4 2025 results beat expectations — Arcus reported EPS of ($0.89) vs. consensus (~$-1.11) and revenue of $33.0M vs. ~$24.9M, which supports the stock strength. Read More. Read More.
• Positive Sentiment: HC Wainwright retains a “Buy” rating and $32 price target — the firm raised several out-year estimates (FY2028, FY2029, FY2030) and bumped some near-term quarters (Q1 and Q2 improvements), signalling confidence in multi-year recovery prospects despite near-term losses. Read More.
• Positive Sentiment: Analyst consensus remains constructive — aggregate analyst coverage shows an average recommendation around “Moderate Buy,” which can support continued buying interest. Read More.
• Neutral Sentiment: Independent rating change: Wall Street Zen upgraded Arcus to Hold — not a strong positive catalyst but reduces downside from previous levels if it was lower. Read More.
• Negative Sentiment: HC Wainwright cut FY2026 and some quarterly EPS forecasts materially — the firm reduced its FY2026 view to ($4.66) from ($4.00) and trimmed FY2027, Q3 and Q4 estimates in places, highlighting continued near-term cash burn and delayed profitability. That deterioration in near-term forecasts is a negative undercurrent despite the Buy rating. Read More.

About Arcus Biosciences

Arcus Biosciences is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel cancer immunotherapies. The company’s research platform centers on modulating tumor microenvironments and immune checkpoints through both small-molecule and antibody-based candidates. Arcus aims to enhance antitumor immune responses by targeting pathways such as the adenosine axis and inhibitory receptors on immune cells.

The company’s lead clinical programs include etrumadenant, an orally administered A2A adenosine receptor antagonist being evaluated in combination with anti-PD-1 therapy, and domvanalimab, an anti-TIGIT monoclonal antibody.